Patient group input was just sent in for the hep C treatment sofosbuvir / velpatasvir. Thank you to all of you who completed PHCN’s sofosbuvir / velpatasvir survey and shared it with others. It was truly an honour to read your responses and to use them to write the patient group input report for the Canadian Agency for Drugs and Technologies in Health (CADTH) on your behalf.
The patient group input reports requested by CADTH are an important step towards getting new treatments for hep C more widely available in Canada and BC.
The sofosbuvir / velpatasvir report was sent in last night. We now wait to hear the outcome of the treatment’s submission. The Hepatitis C Treatment Information Project will keep you apprised of any news.
Sofosbuvir / Velpatasvir
Sofosbuvir / velpatasvir is an all-pill, short-course (possibly only 8 weeks), interferon-free treatment that can be taken with or without ribavirin. In Phase 3 clinical trials, sofosbuvir/velpatasvir (with or without ribavirin) cured an overall 99% of those with genotype 1, 2, 4, 5, or 6 hep C and was found to be well tolerated by patients.
“This drug regimen changes the standard of care in treating patients with HCV. We can now cure almost everyone with a very simple treatment,” said Dr. Jordan Feld, a liver specialist at Toronto Western Hospital.
Hepatitis C Treatment Information Project
PHCN’s Hepatitis C Treatment Information Project is a source of information that doesn’t post a ‘site last modified date’ because it is truly forever changing. Pay it a visit for more information about currently approved hep C treatments, new and emerging drugs, or resources to help in getting ready for treatment. You can also email us your questions about hep C treatments.
Thank you for taking the time to voice your opinion and help advocate for a better tomorrow.